SIS
TSHA icon

Sound Income Strategies’s Taysha Gene Therapies TSHA Stock Holding History

Sound Income Strategies’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-325
Closed -$1.4K – 2242
2026
Q1 		$1.4K Hold
325
– – ﹤0.01% 2235
2025
Q4 		$1.48K Buy
+325
New +$1.58K ﹤0.01% 2212

Other funds holding TSHA

AWM
Affinity Wealth Management Wilmington, Delaware $776M AUM 43.59% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
RRA
Red Reef Advisors Boca Raton, Florida $108M AUM
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
NS
NBC Securities Birmingham, Alabama $1.48B AUM 31.07% 1-Year Est. Return
WN
Williams & Novak Westlake Village, California $151M AUM 27.43% 1-Year Est. Return
LF
Lee Financial Dallas, Texas $783M AUM 23.98% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $43.3B AUM 29.3% 1-Year Est. Return

Sound Income Strategies's TSHA Position: Q2 2026 in Review

Sound Income Strategies sold out of Taysha Gene Therapies (TSHA) in Q2 2026, closing a stake of 325 shares — an estimated $1.4K sold.

Sound Income Strategies first reported a position in TSHA in Q4 2025 and held it in 2 quarters. The position peaked at $1.48K in Q4 2025. 23 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Sound Income Strategies reported no remaining Taysha Gene Therapies position as of Q2 2026 after selling out during the quarter.
  • Sound Income Strategies sold 325 Taysha Gene Therapies shares in Q2 2026, an estimated $1.4K.
  • Sound Income Strategies first reported a position in Taysha Gene Therapies in Q4 2025 and held it in 2 quarters.
  • Sound Income Strategies's Taysha Gene Therapies position peaked at $1.48K in Q4 2025.
  • 23 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Sound Income Strategies's 13F filing for Q2 2026, filed 20 Jul 2026.